Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed the information available for the intellectual disabled population is limited to adults with Down syndrome. This review highlights the important pharmacological and clinical aspects of donepezil, rivastigmine, galantamine and memantine and supports the view that such drugs play an important part in the management of dementia in adults with intellectual disability. Future clinical and research issues are discussed. Copyright © 2004 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Prospective Study of Alzheimer Disease in Down Syndrome
Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362 · cited 2×
“In the UK the National Institute for Clinical Excellence (2001) and in the US the American Academy of Neurology (AAN) (Doody et al., 2001) concluded that antidementia drugs have a significant benefit in patients with AD and that these agents should be made available.”
Background
Cited by
Atypical aging in down syndrome
Zigman, W. B. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1128 · Cited by 260
Therapeutic approaches in the improvement of cognitive performance in Down syndrome
de la Torre, R., & Dierssen, M. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00001-7 · Cited by 53
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
D. Hamlett, E., A. Boger, H., Ledreux, A., M. Kelley, C., J. Mufson, E., F. Falangola, M., N. Guilfoyle, D., A. Nixon, R., Patterson, D., Duval, N., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921095505 · Cited by 46
Synaptic Pathology of Down Syndrome
Garner, C. C., & Wetmore, D. Z. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_20 · Cited by 33
State-of-the-art therapy for down syndrome
Lorenzon, N., Musoles‐Lleó, J., Turrisi, F., Gomis‐González, M., De La Torre, R., & Dierssen, M. (2023) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15517 · Cited by 22
Metadata
- Authors
- Prasher, V. P.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2004-05-17
- Volume
- 19
- Issue
- 6
- Pages
- 509-515
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W2128950732
- Cited by
- 97
- References
- 2
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.